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Amy Duncan1*, Ian Zajac2, Ingrid Flight2, Benjamin JR Stewart1, Carlene Wilson3 and Deborah Turnbull1Abstract
Background: Men have a significantly increased risk of being diagnosed with, and dying from, colorectal cancer
(CRC) than women. Men also participate in fecal occult blood test (FOBT) screening at a lower rate than women.
This study will determine whether strategies that target men’s attitudes toward screening, and matched to stage of
readiness to screen, increase men’s FOBT participation compared to a standard approach.
Methods/Design: Eligible trial participants will be a national sample of 9,200 men aged 50 to 74 years, living in
urban Australia and randomly selected from the Australian electoral roll. Trial participants will be mailed an advance
notification letter, followed 2 weeks later by an invitation letter and a free fecal immunochemical test (FIT) kit. The
intervention is a factorial design, randomized controlled trial (RCT) with four trial arms, including a control. The
content of the advance notification and invitation letters will differ by trial arm as follows: 1) standard advance
notification and standard invitation (control arm); 2) targeted advance notification and standard invitation;
3) standard advance notification and targeted invitation; and 4) targeted advance notification and targeted
invitation. The standard letters will replicate as closely as possible the letters included in the Australian National
Bowel Cancer Screening Program (NBCSP). Modified advance notification and invitation letters will incorporate
additional messages to target men in the precontemplation (advance notification) and contemplation stages
(invitation). The primary outcome is return of the completed FIT within 12 weeks of invitation. Analysts will be
blinded to trial assignment and participants will be blinded to the use of varying invitational materials. Subsamples
from each trial arm will complete baseline and endpoint surveys to measure the psychological impact of the
intervention, and qualitative interviews will be conducted to evaluate attitudes toward the intervention.
Discussion: The outcomes of this study will have implications for the way FOBT screening is offered to men.
Findings will help to identify how invitations for men to screen should be framed and delivered in order to
maximize participation.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12612001122842
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Australia has one of the highest incidence rates of colo-
rectal cancer (CRC) in the world, exceeding Europe,
North America and many other Western countries [1].
In Australia, there are approximately 12,000 new cases
of CRC and 4,500 CRC-related deaths per annum [2].
The risk of CRC significantly increases from the age of
50 years and continues to increase with age [3]. Al-
though CRC can occur in both men and women, men
are 1.4 times more likely to be diagnosed with CRC and
1.5 times more likely to die of CRC than women [4].
Australian longitudinal data also show a 13% increase in
male CRC incidence rates from 1982 to 2007, whereas
female incidence rates over this period remained rela-
tively stable [2]. These data highlight the significance of
CRC as a public health problem in the aging Australian
male population.
Regular screening with fecal occult blood tests (FOBTs)
has been shown to significantly reduce CRC incidence
and mortality by up to 25% in randomized controlled
trials (RCTs) [5]. Consequently, population screening pro-
grams utilizing FOBT screening have been established in
many countries, including Australia, France, Italy and the
UK [6]. The National Bowel Cancer Screening Program
(NBCSP) in Australia currently offers free, mail-delivered
FOBT screening to Australians turning 50, 55, 60 or 65
years of age in any given year, with plans to gradually
extend screening to the broader population [7]. To date,
the NBCSP has offered screening to over 1,500,000
Australians [8]; however, participation in the program is
suboptimal. Recent program data show that of the
685,000 people offered screening in 2008, only 40.1%
completed the test [8]. Low participation in the program
is problematic because it does not permit the program to
achieve its full public health benefit. Given that men have
a significantly higher risk of CRC than women, the finding
that male participation in the program has been consis-
tently lower than female participation is also of concern
[8,9]. In 2008, for example, 36.7% of invited men com-
pleted the FOBT compared to 43.5% of women [8]. This
gender disparity is consistent with FOBT screening data
worldwide. Specifically, large population-based studies in
the USA, Canada and Denmark have demonstrated that
the participation rate of women is 1.2 to 1.8 times higher
than that of men [10-15]. These data highlight the impor-
tance of identifying ways of increasing male participation
in FOBT screening.
In order to identify strategies to improve FOBT par-
ticipation by men, an understanding of the influences on
screening behaviour is important. Several established
theoretical models from the health psychology literature,
including the health belief model (HBM) [16], the theory
of planned behaviour (TPB) [17] and the preventive
health model (PHM) [18], have been utilized to explainscreening intention and behaviour, and form the basis of
many behavioral interventions to improve adherence
[19]. These models posit that cognitive, social and attitu-
dinal constructs all relate to health behaviour decisions.
Manipulation of these constructs is therefore required to
encourage behaviour change.
Our analyses (unpublished), validated across two popula-
tion data sets, found that men who perceive fewer barriers
to FOBT screening, greater benefits, greater self-efficacy
for completing the test, have more sources of social sup-
port who believe they should screen, and are motivated to
comply with societal attitudes and beliefs in regards to
screening (social influence), were more likely to complete
the FOBT. These data were collected via mailed surveys
from two urban, South Australian populations of men and
women aged 50 to 74 years inclusive, and selected at ran-
dom from the Australian electoral roll. Population charac-
teristics and recruitment methods for these samples are
reported in more detail elsewhere [20,21]. Several of these
findings are supported in the wider research literature
[22-24] and provide a useful starting point for the develop-
ment of interventions, to target attitudes toward screening
and encourage screening use in men.
Recent reviews indicate that interventions that target
the needs of population subgroups are more likely to be
effective than a whole population approach [25,26]. Stage
theories, including the transtheoretical model (TTM) of
behaviour change [27], are often utilized to describe readi-
ness to participate in screening and have proved useful for
characterizing the population in order to develop targeted
interventions [28]. These theories deconstruct screening
behaviour into discrete stages of readiness (intention) to
participate in screening and each stage is hypothesized
to be associated with different psychosocial characteris-
tics. Forward progression through the stages is theore-
tically achieved by targeting the variables relevant to the
stage of readiness of the target population [27]. The
TTM describes five sequential stages of readiness to
screen: 1) precontemplation (no intention to participate
in screening); 2) contemplation (intention to participate
in screening); 3) preparation (preparing to participate in
screening); 4) action (participated in screening); and
5) maintenance (sustained screening participation over
regular intervals).
Several studies combining stage theories with the
health behaviour models mentioned previously have
identified differences between participants in the earlier
(precontemplation and contemplation) and later (action
and maintenance) stages of readiness for a variety of
psychosocial constructs. For example, participants in
the earlier stages of readiness have been shown to report
greater barriers to screening [28,29] and have lower per-
ceived CRC risk [29] compared to those in the later
stages who report greater health benefits of screening
Duncan et al. Trials 2013, 14:239 Page 3 of 9
http://www.trialsjournal.com/content/14/1/239[28-31]. These findings suggest that the information needs
of non-participants differ according to readiness to engage
in screening. Interventions aiming to improve participa-
tion are therefore likely to benefit from a stage-matched
approach that targets these needs.
Consistent with a number of international screening
programs [32], the NBCSP invites participants to screen
by the use of mailed invitation letters accompanied by a
free fecal immunochemical test (FIT) [7]. A FIT is a type
of FOBT that does not require dietary restrictions prior to
its use [33]. The current invitation protocol for the NBCSP
operates along a framework consistent with the TTM.
First, participants are mailed an advance notification letter
informing them that within 2 weeks they will receive a
screening package. The aim of the advance notification is
to encourage movement from precontemplation (not yet
thinking about screening) to contemplation (thinking
about screening) [34]. The subsequent invitation letter and
associated screening package then seeks to shift these
participants from contemplation (theoretically achieved by
the advance notification) to the action stage; completing
the FOBT. Although this contact schedule is consistent
with the TTM staging framework, the content of the
letters is not tailored according to the stage that each letter
is designed to target. Including messages that target psy-
chosocial variables relevant to men in these stages has the
potential to encourage stage progression and improve
screening uptake. Specifically, perceived barriers, social in-
fluence and social support all operate at the early stages of
readiness, and should be emphasized in advance notifica-
tion letters; while perceived benefits and self-efficacy ope-
rate at the later stages of readiness, and are best addressed
in communication aimed at invitation [29-31].
The objectives of this study are to determine: 1) whether
invitational strategies that target male attitudes toward
screening, and matched to stage of readiness to screen,
enhance FOBT participation compared to a standard ap-
proach; 2) which combination of targeted and standard
materials are most effective in enhancing participation;
and 3) whether targeted invitational strategies lead to
change in psychosocial variables related to male screening
participation. This study will also explore men’s reactions
to, and evaluation/acceptance of, the invitations.
Methods
Study design
This study is a factorial design, RCT. A national sample
of Australian men aged 50 to 74 years inclusive, will
receive a free, mail delivered FIT, accompanied by either
standard invitational materials (control), invitational
materials modified to target psychosocial variables asso-
ciated with stage of readiness to screen, or a combi-
nation of the standard and modified materials. The
intervention will offer screening to participants consistentwith the protocol utilized by the NBCSP, which includes a
mailed advance notification letter, followed 2 weeks later
by a mailed invitation letter and screening package. The
content of the advance notification and invitation letters
will differ by trial arm. The letters currently utilized by the
NBCSP will serve as the control. The modified advance
notification letter will be designed to target men in the
precontemplation stage, while the modified invitation let-
ter will target men in the contemplation stage.
Participants will be randomized to one of four trial arms
of equal size (allocation ratio 1:1:1:1). Within each trial
arm, participants will be randomized to a survey group, or
a screening only group (allocation ratio 1:2.83). Partici-
pants in the survey group will complete behavioral surveys
measuring the psychosocial variables targeted in the in-
tervention, before commencing the screening phase
(baseline) and again upon its completion (endpoint). Par-
ticipants in the screening only group will receive the
screening offer, without prior study engagement, consis-
tent with the NBCSP. The use of behavioral surveys pre-
and post-intervention will allow the study to examine the
impact of the letters on the psychosocial variables they are
designed to target. However, survey participation will be
restricted to a survey subgroup because of the potential
for completion of the survey to lead to increased screening
awareness for this population.
Upon completion of the screening phase, a purposively
selected subsample of participants in the screening only
group will be invited to participate in semi-structured
interviews to evaluate the intervention. The study design
flow chart is shown in Figure 1.Participants
The names and addresses of 9,200 potential trial parti-
cipants will be randomly selected from the Australian
electoral roll. Men aged 50 to 74 years inclusive, and li-
ving in the urban regions of South Australia, Western
Australia, New South Wales, Victoria and Queensland,
will be eligible. The extract obtained from the electoral
roll will be stratified to reflect the population density of
the five Australian states.
The personal information provided by the Australian
electoral commission will be used specifically for the
purpose of contacting participants via mail, either to re-
cruit participants into the survey group, or to offer a FIT
in a manner equivalent to the NBCSP. Mailed invitations
will include study information and contact details (mail,
email and telephone) for the research team and the
Human Research Ethics Committee, The University of
Adelaide, Australia. Participation is voluntary and parti-
cipants can opt-out of receiving further communication
from the study at any time. Consent procedures for each
phase of the study are described in the relevant sections.
N=9,200 selected 
from electoral roll and 
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Figure 1 Study design.
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Trial participants will be randomly sorted according to an
assigned random integer from 1 through n (total eligible
sample). Subsequently, block randomization will be per-
formed using random allocation software [35] with the
four trial conditions specified, and with random block
sizes of 4, 8 and 12. Participants will then be assigned to
trial conditions according to the randomly assigned inte-
ger and its corresponding trial condition specified in the
block randomization output. Following allocation to trial
conditions, participants will be assigned a random integer
from 1 through n within each condition, and those
assigned integers 1 through 600 in each condition will be
assigned to the survey group for the corresponding trial
arm. Randomization will be performed by a member of
the research team (not the primary investigator) using
de-identified data (participant names will be replaced by a
numerical study identification number).
Survey phases
Participants allocated to the survey group will be invited
to complete a baseline behavioral survey prior to com-
mencing the screening phase of the trial. Participants
will receive a survey advance notification letter by mail,
followed 2 weeks later by the survey package. Reminder
letters will be mailed at 3 and 7 weeks to non-
respondents. Data collection will cease at 12 weeks. Re-
spondents will indicate consent to participate via return
of the completed survey. Survey invitees will receive up
to four letters inviting them to participate in the surveyduring the 12-week data collection period. No further
attempts will be made to recruit non-respondents for ei-
ther the survey, or the screening phase after this period
on the basis that subsequent study invitations could be
construed as harassment. This approach is consistent
with previous population screening research utilizing
electoral roll data [36]. Upon completion of the scree-
ning phase, baseline respondents will be invited to
complete an endpoint survey via the same recruitment
methods utilized for the baseline phase.
The baseline survey will collect demographic data (age,
marital status, education, employment status, country of
birth, language spoken at home and insurance status) and
will obtain a baseline measurement for each of the psy-
chosocial constructs targeted in the intervention (stage of
readiness to screen, perceived barriers, benefits, social
influence, social support, susceptibility and self-efficacy).
Stage of readiness to screen will be measured using a sta-
ging algorithm utilized in previous research [36]. Each
variable will be measured using a number of individual
items and summed for an overall score. Response format
for the psychosocial variables will be a five-point Likert
scale ranging from ‘strongly disagree’ to ‘strongly agree’. It
is anticipated that the surveys will take between 20 and 30
minutes to complete. Survey variables and example items
are summarized in Table 1. The psychosocial measures
and stage of readiness questions will then be repeated
in the endpoint survey, in order to measure change
from baseline to endpoint following exposure to the
intervention.
Table 1 Summary of variables included in the
psychosocial survey and example items
Variable Items Example Reference
Perceived
barriers










Self-efficacy 5 I am confident that I would be
able to screen for bowel cancer
using a home stool test even if




Susceptibility 4 Compared with other persons






4 I want to do what my doctor






11 There is someone I can talk to
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The intervention involves four arms: 1) standard advance
notification letter and standard invitation letter consistent
with the NBCSP (control); 2) targeted advance notification
letter plus standard invitation letter (T1); 3) standard
advance notification letter plus targeted invitation letter
(T2); and 4) targeted advance notification letter and
targeted invitation letter (T3).
Screening will be offered to all baseline survey respon-
dents and participants in the screening only groups
according to the schedule described in Table 2.
Screening packages will include: 1) two-sample FIT
(OC-Sensor, Eiken Chemical Co, Tokyo, Japan); 2)
screening invitation letter; 3) FIT instruction leaflet; 4)
CRC and screening information booklet; 5) participant
details and consent form; and 6) reply paid envelope.
Those who do not participate in the FIT screening offer
within the first 6 weeks will receive a standard reminder
letter irrespective of trial allocation. Consent to partici-
pate in the screening will be obtained via return of the
completed participant details and consent form, and/or
return of the completed FIT.
It is anticipated that some participants invited to
screen will already be up to date with screening or may
not be suitable for screening due to current medical
conditions (for example chronic bowel conditions andTable 2 Screening schedule
Week Study process
Week 1 Mailed advance notification
Week 3 Mailed invitation and screening package
Week 9 Mailed reminder letter to non-respondents
Week 15 Cease data collectionpast CRC diagnosis [40]). Consistent with the NBCSP,
participants will be encouraged to first discuss screening
with their general practitioner and to then contact the
research team if screening is not required. Reasons for
non-participation (for example up to date with screening,
medical reason and no reason provided) will be recorded
for analysis. A screening withdrawal form, where invitees
can provide reasons for non-participation, will be included
in the screening information booklet to assist with
this process, along with telephone and email contact
information.
Letter content
The targeted advance notification and invitation letters
included in the intervention will be based on the stan-
dard letters utilized by the NBCSP and modified
according to best practice guidelines [41-44]. In order to
determine whether the inclusion of targeted material im-
proves screening outcomes over and above the standard
NBCSP information, the modified letters will retain the
content of the control letters in addition to the targeted
messages. Targeted letters will also include changes to
formatting (for example the use of subheadings) consist-
ent with best practice guidelines and to assist with the
organization of the expanded material [41]. All ad-
ditional screening material (for example participant
details form and screening information booklet) will be
designed to mimic as closely as possible the materials
provided in the NBCSP [7]. The following sections de-
scribe each of the intervention letters in more detail.
Advance notification letter
The standard advance notification letter (control) briefly
introduces FIT screening and its purpose, informs partic-
ipants that a FIT package will be mailed to them, and
describes how personal details were obtained and will be
protected. The targeted intervention letter will build on
this standard letter by incorporating additional messages
designed to encourage movement from precontemplation
to contemplation. Specifically, messages will aim to reduce
common barriers to screening (for example ‘the FOBT is
designed to be simple and hygienic’), encourage discus-
sions about screening with sources of social support and
influence (for example ‘if you have any questions about
screening you should talk to your doctor. It may also be
helpful to discuss screening with a family member or a
close friend’) and emphasize CRC susceptibility among
men aged 50 and older (for example ‘although both men
and women can get bowel cancer, it is more likely to occur
in men’).
Screening invitation letter
The standard invitation letter summarizes the content of
the invitation package, emphasizes the importance of
Table 3 Data collection phases and measures obtained
Phase Data collection Measures
Phase
1
Baseline survey mailed to
psychosocial subgroup
(n = 2,400); reminders sent 3
and 7 weeks from initial
mailing
Demographic characteristics:




TTM stage: decision stage for











and invitations; reminders sent
6 weeks after mailing of
invitation
Receipt or non-receipt of
completed FIT, date of return
of FIT, reasons for opt-out





Endpoint survey mailed to
baseline survey respondents
(n = 1,200, estimated);
reminders sent 3 and 7 weeks
from initial mailing
TTM stage and psychosocial






phase from focus groups,
including participants from
each of the trial arms
Why participants chose or
chose not to use the FIT.




FIT, fecal immunochemical test; TTM, transtheoretical model.
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describes how FIT results will be processed and returned.
The targeted invitation will include messages designed to
encourage movement from contemplation to action. This
letter will include messages designed to improve percep-
tions of the benefits of participating in the FIT (for
example ‘screening for bowel cancer using a fecal occult
blood test can reduce the chances of dying from bowel
cancer’) and to increase self-efficacy for completing the
test (for example ‘the step-by-step instructions will help
you to complete the test even if you have never done a test
like this before’). As with the advance notification, suscep-
tibility to CRC among men will also be emphasized.
Qualitative evaluation
Following the screening phase, a purposively selected
group of participants from the screening only groups
will be invited to take part in semi-structured telephone
interviews to explore men’s reactions to, and satisfaction
with, the intervention. Participants invited to qualitative
interviews will be selected utilizing maximum variation
sampling to ensure the subsample varies by age, inter-
vention group and participation in the screening offer.
Invitations will be sent by mail, and will include an
opt-in form, study information, research team and
HREC contact details, and a reply paid envelope. Those
wishing to participate in the interviews will be asked to
contact the research team (by telephone, email or return
of the opt-in form) to indicate willingness to be involved
in the interviews. Verbal consent will be obtained prior
to the interview.
It is estimated that the qualitative interviews will last
between 15 and 30 minutes and will be conducted one-
on-one using computer assisted telephone interviewing
(CATI). Questions will focus on: 1) why participants
chose or chose not to use the FIT; 2) reactions to, and
satisfaction with, the intervention; and 3) how partici-
pants feel the intervention materials could be improved.
Interviews will be audio recorded and transcribed prior
to analysis.
Outcomes
The primary outcome will be participation in the screen-
ing test, defined as return of the completed FIT within
12 weeks of the invitation. Secondary outcomes (stage of
change, psychosocial variables and qualitative evaluation)
will be collected via the baseline and endpoint surveys,
and the qualitative evaluation. The data collected during
each phase is summarized in Table 3.
Sample size considerations
Assuming a 50% return of the baseline survey, screening
will be offered to a total of 8,000 participants (1,200 sur-
vey participants and 6,800 screening only participants).Participants who contact the research team and opt-out
of screening due to: 1) recent FOBT screening; 2) recent
colonoscopy; 3) recent bowel cancer diagnosis; or 4)
medical condition that prevents the use of FOB-based
screening tests, will be excluded from analysis on the
basis that screening is not suitable/required for this
group [3]. Those who opt-out of screening for reasons
other than those listed previously (for example did not
want to complete the screening) will be categorized as a
non-participant for the purpose of analyses. Survey
group participants who opt-out of the study prior to
completing the endpoint phase will be excluded from
analyses involving survey data.
Two participation rates will then be calculated for
each trial arm: 1) inclusive of survey participants (2,000
per trial arm); and 2) exclusive of survey participants
(1,700 per trial arm). Analyses will be conducted both
with and without the inclusion of survey participants
because participation for this subgroup is likely to be
higher due to the baseline survey acting as a prompt for
screening participation. Assuming a participation rate of
at least 40% for the control group and allowing for up to
40% of invited participants to be excluded due to being
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the detection of differential FOBT uptake of at least 6%
between any two groups with at least 80% power. A dif-
ference of at least 6% was considered by the research
team to be the smallest difference that would be feasible
to detect without requiring overly large sample sizes,
and is similar to the effect size estimate used in our
previous research [36].
Blinding
Data collectors and analysts will be blinded to trial allo-
cation following initial randomization. Data analysts will
become unblinded following analysis of the primary out-
come for reporting purposes. All trial participants will
receive an invitation to screen for free as part of a large
male health study, but will remain blinded to the use of
varying invitational techniques across trial conditions.Statistical analyses
Primary outcome
A 2 x 4 (participation by intervention group) chi-squared
test with alpha set at 0.05 will compare FIT participation
rates between groups. Potential covariates such as demo-
graphic factors (age and socioeconomic status) and psy-
chosocial variables (survey sample only) will be checked
by the change in coefficient method using log binomial
generalized linear models.Secondary outcomes
Change in psychosocial variables from baseline to
endpoint will be calculated for the participants who
complete both surveys. Change scores will be calculated
by subtracting baseline from endpoint scores for each of
the variables targeted by the intervention. These change
scores will then be compared between intervention groups
using analysis of covariance (ANCOVA), controlling
for potential co-variation from demographic variables.
Based on the predicted group sizes mentioned above,
the ANCOVA using two-tailed significance will have
80% power to detect a difference of at least half a
standard deviation for psychosocial variables between
any two groups.
Qualitative data collected via telephone interviews will
be analyzed using the framework analysis method re-
commended for applied health research by Green and
Thorogood [45]. This method is suited to applied health
research as it allows for the exploration of themes de-
rived from a priori aims relevant to this research stage
as well as emergent themes raised by respondents. The
study will aim to recruit 20 screening participants and
20 non-participants for interview in order to achieve
data saturation [45].Ethical considerations
This trial has been approved by the Human Research
Ethics Committee, The University of Adelaide, Australia.
Discussion
This project will identify whether recruitment strategies
targeted to stage of readiness to screen, and the variables
known to influence men’s movement to a higher stage,
are effective in encouraging men to participate in FIT
screening. The outcomes will provide information con-
cerning how messages can be framed and delivered, in
order to maximize participation in population screening
programs in Australia and globally. If this study shows
that a stage-matched intervention that addresses male
concerns improves participation, the information may be
useful for optimizing male participation in alternative
forms of screening and preventive health practices.
Future research incorporating a female population would
be required to establish whether differences in participa-
tion result from the gendered information, or are a con-
sequence of the overall improvements made to the
screening invitation letters.
This study is among the first to dedicate a specific
focus to understanding male screening behaviour. While
several national screening initiatives exist for women in
Australia (for example breast and cervical cancer scree-
ning programs) the NBCSP is the first nationally funded
screening program to include men [7]. This study will
collect extensive data on male attitudes toward screening
through the use of quantitative surveys and qualitative
interviews, and the results may also have important im-
plications for future interventions.
A potential limitation of the study is that while the inter-
vention aims to replicate the invitation protocol of
the NBCSP, it will not be undertaken in collaboration with
the national program. It is therefore likely that some of the
participants invited to screen in this study may have re-
cently participated, or are about to participate, in the
NBCSP. To account for this potential limitation, partici-
pants will be encouraged to contact the research team
when participation in other screening programs is the rea-
son for declining the study offer. We acknowledge that
this approach also has its limitations because it re-
quires participants to actively volunteer the information to
the research team, and because self-reported screening
adherence can be inaccurate [46]. Consequently, participa-
tion rates observed in this study may be smaller than
would occur for a population not exposed to other screen-
ing programs and will be considered in the reporting of
results.
Trial status
Surveys were mailed to individuals in the survey sub-
group from 1 October 2012 and data collection for this
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offered to baseline survey participants and remaining
trial participants in March 2013. This phase lasted for 3
months and concluded in June 2013. Data collection
for the endpoint survey and recruitment of trial partici-
pants to the qualitative group will occur simultaneously
upon completion of the screening phase. It is antici-
pated that all data will be collected by September 2013.
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